SCHEMBL1259282

SCHEMBL1259282

CCCCC/C=C\C/C=C\CCCCCCCCCS(=O)(=O)O.CCCCC/C=C\C/C=C\CCCCCCCCCS(=O)(=O)O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.69
FAAH O00519 1/20 0.66
ALDH1A1 P00352 4/20 0.56
KDM4E B2RXH2 3/20 0.56
F7 P08709 3/20 0.56
F3 P13726 3/20 0.56
PPARG P37231 3/20 0.56
PPARD Q03181 2/20 0.56
PPARA Q07869 2/20 0.56
FABP3 P05413 2/20 0.56
FFAR1 O14842 2/20 0.56
DUSP3 P51452 1/20 0.56
PTPN7 P35236 1/20 0.56
LMNA P02545 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP19A1 P11511 1/20 0.56
FABP4 P15090 1/20 0.56
HPGD P15428 1/20 0.56
ALOX15 P16050 1/20 0.56
TSHR P16473 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1533680 1.00 EPHX2 (0.69) EPHX2FAAHALDH1A1KDM4EF7
SCHEMBL2637148 1.00 EPHX2 (0.69) EPHX2FAAHALDH1A1KDM4EF7
SCHEMBL3458829 1.00 EPHX2 (0.69) EPHX2FAAHALDH1A1KDM4EF7
SCHEMBL2637146 1.00 EPHX2 (0.69) EPHX2FAAHALDH1A1KDM4EF7
SCHEMBL8985935 1.00 EPHX2 (0.69) EPHX2FAAHALDH1A1KDM4EF7
SCHEMBL8985933 1.00 EPHX2 (0.69) EPHX2FAAHALDH1A1KDM4EF7
SCHEMBL11370740 0.94 EPHX2 (0.75) EPHX2FAAHF7F3PPARG
SCHEMBL2219389 0.94 EPHX2 (0.75) EPHX2FAAHF7F3PPARG
SCHEMBL8349583 0.94 EPHX2 (0.75) EPHX2FAAHF7F3PPARG
SCHEMBL1962429 0.94 EPHX2 (0.75) EPHX2FAAHF7F3PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110092739-A1 Lipid Nanoparticle Based Compositions and Methods for the Delivery of Biologically Active Molecules SIMA THERAPEUTICS, INC. (US) 2011-04-21 US disclosed
US-7893302-B2 novel cationic lipids based on 4-(aminomethyl)-1,2-bis-(fatty ether or ester)-benzene SIRNA THERAPEUTICS, INC. (US) 2011-02-22 US disclosed
US-20100048888-A1 Lipid Nanoparticle Based Compositions and Methods for the Delivery of Biologically Active Molecules SIRNA THERAPEUTICS, INC., A WHOLLY OWNED SUBSIDIARY OF MERCK & CO., INC. 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092739-A1 Lipid Nanoparticle Based Compositions and Methods for the Delivery of Biologically Active Molecules PHAX, CETP, LIPC EPHX2 873/4885FAAH 1624/4885ALDH1A1 3283/4885
US-20100048888-A1 Lipid Nanoparticle Based Compositions and Methods for the Delivery of Biologically Active Molecules PHAX, CETP, LIPC EPHX2 929/4885FAAH 1505/4885ALDH1A1 3348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.